Observational studyMedicine2025
Comparative study of clinical characteristics and long-term prognosis between macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae infections in children: A retrospective case-control study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serum HMGB3 and PCSK9 Levels as Predictors of Early Treatment Response in PediatricInternational journal of general medicine · 2026Article
- Clinical characteristics ofTranslational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to investigate the long-term health impacts of macrolide-resistant macrolide-resistant Mycoplasma pneumoniae (MRMP) infection in children, identify factors influencing MRMP infection, and provide evidence for clinical decision-making to improve prognosis and address challenges posed by antimicrobial resistance. A case-control study was conducted, enrolling 64 pediatric MRMP-infected patients (research group) and 266 macrolide-sensitive macrolide-sensitive M pneumoniae-infected patients (control group) admitted to our hospital from August 2023 to April 2024. All participants underwent standardized evaluations, including physical examinations, medical history review, complete blood count, blood biochemistry, inflammatory marker assays, and immunological profiling. The research group exhibited a lower incidence of fever compared to the control group (P < .01). Respiratory assessments revealed significantly reduced rates of wet rales, intercostal retractions, and lung consolidation in the research group (P < .001). Hematologically, the research group demonstrated lower white blood cell counts (P < .05). Biochemical analysis indicated decreased alanine aminotransferase and urea levels (P < .05), elevated lactate dehydrogenase (P < .05), and comparable creatine kinase and creatine kinase-MB (CK-MB) levels between groups. C-reactive protein was significantly elevated in the research group (P < .001), while immunoglobulin G (IgG), immunoglobulin A (IgA), and immunoglobulin E (IgE) levels remained comparable. Multivariate logistic regression analysis adjusting for potential confounders identified lung consolidation (OR = 65.79, 95% CI: 20.86-207.49) and alanine aminotransferase levels (OR = 0.90, 95% CI: 0.82-0.99) as independent predictors of MRMP infection (P < .05). MRMP and macrolide-sensitive M pneumoniae infections in children present distinct clinical profiles and long-term prognoses. MRMP-infected children demonstrate elevated risks of recurrent respiratory infections and potential long-term respiratory sequelae, underscoring the necessity for rigorous acute-phase lung consolidation monitoring and extended respiratory function surveillance to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.